Catalytic properties of 26 S and 20 S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities* by Reidlinger, Jutta et al.
Catalytic Properties of 26 S and 20 S Proteasomes and
Radiolabeling of MB1, LMP7, and C7 Subunits Associated
with Trypsin-like and Chymotrypsin-like Activities*
(Received for publication, May 27, 1997)
Jutta Reidlinger‡, Angela M. Pike‡§, Peter J. Savory‡, Rachael Z. Murray and
A. Jennifer Rivett¶i
From the Department of Biochemistry, University of Bristol, School of Medical Sciences, Bristol, BS8 1TD,
United Kingdom
20 and 26 S proteasomes were isolated from rat liver.
The procedure developed for the 26 S proteasome re-
sulted in greatly improved yields compared with previ-
ously published methods. A comparison of the kinetic
properties of 20 and 26 S proteasomes showed signifi-
cant differences in the kinetic characteristics with cer-
tain substrates and differences in the effects of a protein
substrate on peptidase activity. Observed differences in
the kinetics of peptidylglutamyl peptide hydrolase ac-
tivity suggest that the 26 S complex cannot undergo the
conformational changes of 20 S proteasomes at high con-
centrations of the substrate benzyloxycarbonyl (Z) -Leu-
Leu-Glu-b-naphthylamide. Various inhibitors that dif-
ferentially affect the trypsin-like and chymotrypsin-like
activities have been identified. Ala-Ala-Phe-chloro-
methyl (CH2Cl) inhibits chymotrypsin-like activity as-
sayed with succinyl (Suc) -Leu-Leu-Val-Tyr-AMC, but
surprisingly not hydrolysis of Ala-Ala-Phe-7-amido-
4-methylcoumarin (AMC). Tyr-Gly-Arg-CH2Cl inhibits
Suc-Leu-Leu-Val-Tyr-AMC hydrolysis as well as trypsin-
like activity measured with t-butoxycarbonyl (Boc)
-Leu-Ser-Thr-Arg-AMC, while Z-Phe-Gly-Tyr-diazo-
methyl (CHN2) was found to inhibit only the two chy-
motrypsin-like activities. Radiolabeled forms of pepti-
dyl chloromethane and peptidyl diazomethane
inhibitors, [3H]acetyl-Ala-Ala-Phe-CH2Cl, [
3H]acetyl-
and radioiodinated Tyr-Gly-Arg-CH2Cl, and Z-Phe-Gly-
Tyr-(125I-CHN2), have been used to identify catalytic
components associated with each of the three peptidase
activities. In each case, incorporation of the label could
be blocked by prior treatment of the proteasomes with
known active site-directed inhibitors, calpain inhibitor
1 or 3,4-dichloroisocoumarin. Subunits of labeled pro-
teasomes were separated either by reverse phase-HPLC
and SDS-polyacrylamide gel electrophoresis or by two-
dimensional polyacrylamide gel electrophoresis fol-
lowed by autoradiography/fluorography and immuno-
blotting with subunit-specific antibodies. In each case,
label was found to be incorporated into subunits C7,
MB1, and LMP7 but in different relative amounts depend-
ing on the inhibitor used, consistent with the observed
effects on the different peptidase activities. The results
strongly suggest a relationship between trypsin-like ac-
tivity and chymotrypsin-like activity. They also help to
relate the different subunits of the complex to the as-
sayed multicatalytic endopeptidase activities.
The 20 S proteasome (multicatalytic proteinase complex) is a
high molecular mass (700 kDa) multimeric proteinase that is
found in all types of eukaryotic cells (1–4). It can be isolated by
itself but also forms the catalytic core of the 26 S proteasome
(5). Proteasomes are found both in the nucleus and cytoplasm
and play a major role in both ubiquitin-dependent and ubiq-
uitin-independent nonlysosomal pathways of intracellular pro-
tein turnover. They have also been implicated in the pathway
by which antigens are processed for presentation by major
histocompatibility complex (MHC)1 class I molecules (reviewed
in Refs. 6 and 7).
Proteasomes (20 S forms) are cylindrical particles that are
composed of subunits of molecular mass of 20–35 kDa. Those
isolated from archaebacteria (Thermoplasma) contain only two
different types of subunit, which has made them a useful model
for structural studies (8). Yeast proteasomes contain fourteen
different subunits (9), but in animal cells there are additional
non-essential subunits that are g-interferon-inducible and con-
tribute to antigen processing (e.g. Refs 10–13). All proteasomal
subunits are encoded by members of the same gene family but
they can be divided into two groups, a and b, based upon their
similarity to either the a or b subunit of the archaebacterial
proteasome. The structure forms a complex dimer made up of
four rings with seven subunits in each ring (14).
Binding of regulatory complexes to the ends of the cylindrical
structure can enhance the catalytic activity of proteasomes. 26
S proteasomes are composed of 20 S proteasome with 19 S
(ATPase, PA700) complexes that contain many different sub-
units (15,16). Only the 26 S proteasome is able to degrade
protein substrates such as polyubiquitinated proteins and or-
nithine decarboxylase in an ATP-dependent process. The pep-
tidase activity of the 20 S proteasome is greatly enhanced upon
binding of PA28 (11 S regulator), a 180-kDa hexamer consist-
ing of two different subunits (17, 18). PA28 has been implicated
in the antigen presentation pathway (19) and is inducible by
g-interferon.
The recent identification of a threonine residue as the cata-
lytic nucleophile of proteasomes (20) has clearly shown that
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they represent a novel family of proteolytic enzymes. Eukary-
otic proteasomes have multiple proteolytic activities that have
been widely referred to as trypsin-like, chymotrypsin-like, and
peptidylglutamyl-peptide hydrolase activities. Isolation of
yeast mutants defective in proteasome chymotrypsin-like or
peptidylglutamyl-peptide hydrolase activity has allowed iden-
tification of several b-type subunits of the yeast proteasome
that influence catalytic activities (21–24), but even with the
recently published structure of the yeast proteasome (25) many
questions remain to be answered.
So far there is rather limited information available regarding
functions of individual subunits of the mammalian complex
where the situation is complicated by the additional b-type
subunits. Three of the mammalian b-type subunits, as well as
three non-essential g-interferon-inducible subunits that can
replace them, have putative catalytic N-terminal threonine
residues, but the other four b subunits do not.
Inhibitor studies with both rat liver and bovine pituitary
proteasomes have shown that there are at least five distinct
peptidase sites within the mammalian complex (e.g. Refs. 26–
29). More recent efforts to investigate inhibitors of the different
peptidase activities of proteasomes have not really clarified the
situation, and it is still not clear how these measured activities
relate to the many different subunits of the complex. One
subunit, MB1(X), has been identified as the major target for
inhibition by lactacystin (30). Identification of the catalytic
components responsible for the known activities is essential for
a further understanding of the multiple peptidase activities of
this multifunctional complex.
In this study2 we have investigated aspects of the the kinetic
properties of 20 and 26 S proteasomes isolated from rat liver.
To make a direct determination of catalytic subunits associated
with the distinct peptidase activities, we have prepared radio-
labeled forms of three peptidyl chloromethane and peptidyl
diazomethane inhibitors of proteasomes (31) that differentially
affect the trypsin-like activity and two chymotrypsin-like ac-
tivities. The results demonstrate direct labeling of subunits
associated with these activities.
EXPERIMENTAL PROCEDURES
Materials—Rats (Wistar) were obtained from the University of
Leicester Biomedical Services Unit or at the University of Bristol.
Boc-Leu-Ser-Thr-Arg-4-amidomethylcoumarin (AMC) was purchased
from the Peptide Institute, Japan. Ala-Ala-Phe-AMC, succinyl-Leu-
Leu-Val-Tyr-AMC, Z-Leu-Leu-Glu-b-naphthylamide, trypsin, Ala-Ala-
Phe-CH2Cl and glutaraldehyde were from Sigma Chemical Co. Tyr-Gly-
Arg-CH2Cl and Z-Phe-Gly-Tyr-CHN2 were prepared as described (31,
32). N-succinimidyl-3-(2-pyridyldithio)-propionate was from Boehringer
Mannheim. 4-(2-aminoethyl)-benzenesulfonyl fluoride (Pefabloc) was
obtained from Life Technologies, Inc. Na125I (specific activity 2170
Ci/mmol) and [3H]acetic anhydride (specific activity 5 Ci/mmol) were
purchased from Amersham.
Purification of 20 and 26 S Proteasomes—20 S proteasomes were
purified from fresh or frozen rat livers as described (27). For the puri-
fication of 26 S proteasomes, the early steps were based on a published
procedure (33) but later steps were designed to improve the yield.
Briefly, 100 g rat livers were homogenized in 3–4 volumes of buffer A
(20 mM Tris/HCl, pH 7.0, containing 5 mM ATP, 1 mM mercaptoethanol,
0.1 mM EDTA, and 20% (v/v) glycerol). After removing cell debris from
the homogenate by centrifugation at 100,000 3 g for 60 min, the 26 S
proteasome was sedimented by centrifugation at 140,000 3 g for 6 h.
The pellet was resuspended in buffer A and incubated with 20 ml of
Biogel hydroxylapatite equilibrated in buffer A for 30 min. Unbound
material was concentrated using an Amicon XM 50 membrane and
layered on 6 sucrose gradients (10–30% sucrose in buffer A without
glycerol, 31 ml each) and spun for 16 h at 113,000 3 g. Fractions
containing 26 S proteasome activity were pooled, concentrated, and
loaded onto a Superose-6 column (Pharmacia 16/50, 50 mg of protein
per run) equilibrated with 20 mM Tris/HCl, pH 7.5, containing 2 mM
ATP, 1 mM mercaptoethanol, 100 mM NaCl, and 10% (v/v) glycerol.
Active fractions were pooled and then applied to a Resource Q column
(Pharmacia Biotech Inc., 1 ml) equilibrated with 20 mM Tris/HCl, pH
7.5, containing 1 mM mercaptoethanol and 10% (v/v) glycerol. The
enzyme was eluted using a linear gradient from 0 to 500 mM NaCl in the
equilibration buffer. Active fractions were concentrated and applied to
a Superose-6 gel filtration column (Pharmacia 10/30) equilibrated in the
same buffer as the earlier gel filtration step. All steps apart from those
involving fast protein liquid chromatography were performed at 0–
4 °C. The purified 26 S proteasome preparation was dialyzed against
buffer A containing 1 mM dithiothreitol instead of mercaptoethanol and
stored either on ice or at 220 °C.
The purity of proteasome preparations was judged by SDS-PAGE
(34), and protein concentrations were determined by the Bradford
method (35) using bovine serum albumin as standard.
Proteasome Assays—Peptidase activities of 20 S proteasomes were
assayed with synthetic peptide substrates in 50 mM Hepes buffer, pH
7.5 or 8.0, as described previously (27). For the continuous assays, data
were analyzed using FluSys software kindly provided by Rawlings and
Barrett (36). Trypsin-like activity was assayed with 50 mM Boc-Leu-Ser-
Thr-Arg-AMC, chymotrypsin-like activities were assayed with 50 mM
Ala-Ala-Phe-AMC and 50 mM Suc-Leu-Leu-Val-Tyr-AMC, and peptidyl-
glutamyl peptide hydrolase activity was assayed with Z-Leu-Leu-Glu-
nap as substrates. Inhibitor studies with 20 and 26 S proteasomes were
carried out by assaying peptidase activities after preincubation of en-
zyme with inhibitor for 30 min at 25 °C. Further details are given in
figure and table legends.
Radiolabeling of Ala-Ala-Phe-CH2Cl, Tyr-Gly-Arg-CH2Cl, and Z-
Phe-Gly-Tyr-CHN2—Iodination of the inhibitors containing tyrosine
was carried out using iodobeads from Pierce (37). I-Tyr-Gly-Arg-CH2Cl
and 125I-Tyr-Gly-Arg-CH2Cl were prepared by incubating 3 mM NaI or
3 mM Na125I (1 mCi), respectively, in a 1 mM solution of Tyr-Gly-Arg-
CH2Cl in 100 mM sodium phosphate buffer, pH 7.0, with Iodobeads
according to the manufacturer instructions. The reaction was stopped
after 15 min by the removal of the solution from the Iodobeads. Radio-
iodinated Z-Phe-Gly-Tyr-CHN2 was prepared in a similar manner.
Acetylation of Ala-Ala-Phe-CH2Cl and Tyr-Gly-Arg-CH2Cl with ace-
tic anhydride or [3H]acetic anhydride was carried out by the method of
Rauber et al. (32). The acetylated products were lyophilized and puri-
fied by reverse phase-HPLC on a Vydac C18 column (4.6 3 250 mm)
with a linear gradient of 0–70% acetonitrile in 0.1% trifluoroacetic acid.
HPLC analysis yielded one major peak of absorbance at 274 nm that
contained .70% of the eluted radioactivity. The identity of the products
was confirmed by electrospray mass spectrometry (kindly performed by
G. Eaton, Department of Chemistry, University of Leicester).
Affinity Labeling of Proteasomes—Purified 20 S proteasomes (0.5
mg/ml) were incubated with 100 mM 125I-Tyr-Gly-Arg-CH2Cl or Z-Phe-
Gly-Tyr(125I-CHN2) in 50 mM sodium phosphate buffer, pH 7.0, for 2 h
at 20 °C. Excess 125I and unbound inhibitor were removed using two
successive Sephadex G-25 PD10 columns (Pharmacia), and the enzyme
was concentrated to 3–5 mg/ml using a Centricon 30 concentrator
(Amicon). In experiments designed to investigate the blocking of en-
zyme labeling by pretreatment with known active site-directed inhibi-
tors, proteasomes (0.1 mg/ml) were preincubated with 3,4-dichloroiso-
coumarin (5 mM) or calpain inhibitor 1 (10 mM) in 50 mM sodium
phosphate buffer, pH 7.0, for 30 min at 20 °C. Labeling with [3H]acetyl-
Tyr-Gly-Arg-CH2Cl (50 mM) was performed in the same way as de-
scribed for the iodinated inhibitor except that incubations with labeled
inhibitor were for 2.5 h. Labeling with [3H]acetyl-Ala-Ala-Phe-CH2Cl
was carried out as described in figure and table legends.
Analysis of Labeled Subunits—Labeled proteasome samples (50 mg)
were analyzed by two-dimensional polyacrylamide gel electrophoresis
(38) followed by autoradiography or fluorography of dried or electro-
blotted gels using Kodak X-Omat AR film. Labeled proteasome subunits
were also identified by reverse phase-HPLC. Samples were loaded onto
a Vydac C4 column (250 3 4.6 mm), and subunits were eluted with a
flow rate of 0.3 ml/min and a gradient of 0–35% acetonitrile in 0.1%
trifluoroacetic acid for 10 min followed by 35–55% acetonitrile plus 0.1%
trifluoroacetic acid in 2.5 h. Radiolabeled peaks were identified by
counting fractions in a g or scintillation counter as appropriate.
The labeled peaks from the HPLC were lyophilized to dryness, re-
dissolved in SDS-PAGE sample buffer, run on SDS-PAGE gels, and
then electroblotted on to nitrocellulose (39). Blotted proteins were vis-
ualized with Ponceau S, and labeled bands were identified by autora-
diography/fluorography (usually 2 weeks at 270 °C) followed by immu-
noblot analysis (40). Radiolabeled subunits were also identified by their
position on two-dimensional-PAGE gels by N-terminal sequence anal-
2 Part of this work was carried out in the Department of Biochemis-
try, University of Leicester, Leicester LE1 7RH, UK.
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ysis for unblocked subunits (41) and by immunoblot analysis (42).
Tryptic Digestion and Protein Sequencing—Labeled proteasomes or
isolated subunits were subjected to carboxacetamidation prior to diges-
tion with trypsin (5% w/w) in 50 mM Tris/HCl, pH 7.2, for 6 h. The
tryptic peptides were purified by reverse phase-HPLC using a Vydac
C18 column with a flow rate of 0.5 ml/min and a gradient of 0–70%
acetonitrile in 0.1% trifluoroacetic acid over 2 h. Purified labeled pep-
tides were covalently attached to Sequelon-AA membranes (Millipore
Corp.) following the manufacturer instructions. Sequence analysis of
peptides was carried out by automated Edman degradation using an
Applied Biosystems model 470A gas-phase sequencer equipped with a
model 120A phenylthiohydantoin amino acid analyzer (41).
Antibodies and Immunoblotting—Polyclonal antibodies against a
C7-derived peptide (GYELSPTAAANFTRC) corresponding to residues
72–85 of rat and human C7 with an added cysteine residue) were kindly
provided by Dr. K. B. Hendil (University of Copenhagen) (14). The
antiserum reacted exclusively with subunit C7 in blots from two-dimen-
sional-PAGE gels of purified proteasomes (42). Other subunit-specific
polyclonal antibodies used include those raised in rabbits against re-
combinant rat LMP7 (43) and monoclonal antibodies as described by
Hendil and co-workers (42). Polyclonal antibodies against human
MECL1 (44) were kindly provided by G. Foss. Immunoblotting was
carried out as described previously (40).
RESULTS
Purification and Kinetic Properties of the 26 S Proteasome—
The purification procedure developed for 26 S proteasomes
resulted in apparently homogeneous preparations as judged by
nondenaturing PAGE and showed subunit patterns on SDS-
PAGE (Fig. 1), similar to 26 S proteasomes isolated from other
sources (15, 16). The yield of 26 S proteasome was typically 1–3
mg from 100 g of rat liver compared with 0.5 mg from 500 g of
rat liver reported by Ugai et al. (33).
The rate of hydrolysis of Suc-Leu-Leu-Val-Tyr-AMC and
Boc-Leu-Ser-Thr-Arg-AMC by 26 S proteasome preparations
was found to be approximately ten times that of 20 S protea-
somes with a similar Km value (58 mM for Suc-Leu-Leu-Val-Tyr-
AMC). The specific activity with Ala-Ala-Phe-AMC was not
very different between the 20 and 26 S proteasomes. However,
there was a striking difference in the peptidylglutamyl peptide
hydrolase activity. We have previously shown that rat liver 20
S proteasomes have two activities: LLE1 with a Km value for
Z-Leu-Leu-Glu-nap of 0.07 mM and LLE2 which shows positive
co-operativity with a K0.5 value of 0.28 mM (46). The 26 S
proteasomes by comparison displayed Michaelis-Menten kinet-
ics over a wide range of concentrations of this substrate (Fig. 2)
with a Km value of 0.1 mM and no distinct LLE2 activity.
Another striking difference between 20 and 26 S proteasome
preparations is the effect of substrate protein on the rate of
hydrolysis of synthetic peptide substrate. Casein inhibits hy-
drolysis of Suc-Leu-Leu-Val-Tyr-AMC, Z-Leu-Leu-Glu-nap,
and to a lesser extent Boc-Leu-Ser-Thr-Arg-AMC by 20 S pro-
teasomes but slightly stimulates the hydrolysis of these sub-
strates by 26 S proteasomes (Table I).
Inhibitor Characteristics of 20 and 26 S Proteasomes—Acti-
vated forms of proteasomes have been reported to be more
sensitive to inhibition by some compounds. The effects of a
variety of peptidyl aldehyde, chloromethane, and diazometh-
ane inhibitors were tested on both 20 S and 26 S proteasome
preparations to determine whether the higher specific activity
of 26 S proteasomes meant that they could also be inhibited
more rapidly. In general, this was found not to be the case, and
the effect of inhibitors was similar for 20 and 26 S proteasomes
(Table II). Ala-Ala-Phe-CH2Cl only partially inhibits 20 S pro-
teasomes and, surprisingly, inhibits hydrolysis of Suc-Leu-Leu-
Val-Tyr-AMC but not that of Ala-Ala-Phe-AMC by proteasomes
(31). Both the rate and extent of inactivation with Ala-Ala-Phe-
CH2Cl was identical for 20 and 26 S proteasomes (Fig. 3), and
in neither case did further additions of inhibitor cause further
inhibition of Suc-Leu-Leu-Val-Tyr-AMC hydrolysis.
The radiolabeled forms of Ala-Ala-Phe-CH2Cl, Tyr-Gly-Arg-
CH2Cl, and Z-Phe-Gly-Tyr-CHN2 were prepared since these
are potential affinity labels for identification of subunits asso-
ciated with the different activities. They inhibited the trypsin-
like and chymotrypsin-like activities to different extents while
the peptidylglutamyl peptide hydrolase activity was unaffected
or even slightly stimulated by these reagents. Since there ap-
peared to be no significant differences in reactivity with 20 and
26 S proteasomes, 20 S preparations were used for all of the
studies with radiolabeled inhibitors because of their relative
ease of purification and greater stability compared with 26 S
proteasomes.
Little difference was observed in the inhibition of proteasome
activities by radiolabeled and unlabeled forms of the peptidyl
chloromethanes and peptidyl diazomethane inhibitors (Table II).
TABLE I
Effect of casein on peptidase activities of 20 and 26 S proteasomes
Assays were performed as described under “Experimental Proce-
dures” using 0.5 and 2 mg of enzyme for 26 and 20 S proteasome,
respectively. The substrate concentration was 40 mM for LSTR (Boc-
Leu-Ser-Thr-Arg-AMC), LLVY (Suc-Leu-Leu-Val-Tyr-AMC), and AAF
(Ala-Ala-Phe-AMC). LLE (Z-Leu-Leu-Glu-nap) was used at 0.4 mM for
the 26 S proteasome and at 0.1 mM for the 20 S proteasome. The casein
concentration was 0.1 mg/ml. Values are given as the average of two
separate experiments, each performed in triplicate.
Proteasomes
Activity with casein added (% of control without added casein)
with substrate
LSTR LLVY AAF LLE
26 S 116.3 6 3.5 119.1 6 3.0 113.0 6 2.8 115.8 6 1.7
20 S 68.9 6 1.9 33.7 6 1.6 102.0 6 2.5 52.1 6 4.1
FIG. 1. SDS-PAGE of purified 26 S proteasomes. 26 S protea-
somes (5 mg) were separated on 12.5% gels, and protein was visualized
by silver staining (45).
FIG. 2. Peptidylglutamyl peptide hydrolase activity of 26 S
proteasomes. Enzyme activities of the purified 26 S proteasomes (0.5
mg/assay) were assayed in 50 mM Hepes/KOH, pH 8.0, incubated for 20
min at 37 °C. From the inset, a Km value of 0.1 mM was obtained.
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The rate of inactivation was found to be identical with Ala-
Ala-Phe-CH2Cl and [
3H]acetyl-Ala-Ala-Phe-CH2Cl (Fig. 3).
Tyr-Gly-Arg-CH2Cl, which might be predicted to be a specific
inhibitor for trypsin-like activity because of the arginine resi-
due in the P1 position, was found to inhibit trypsin-like activity
and also chymotrypsin-like activity measured with Suc-Leu-
Leu-Val-Tyr-AMC but not that assayed with Ala-Ala-Phe-AMC
(Table II). Two radiolabeled forms of Tyr-Gly-Arg-CH2Cl were
prepared: 125I-Tyr-Gly-Arg-CH2Cl and [
3H]-acetyl-Tyr-Gly-
Arg-CH2Cl. Both of these reagents were found to inhibit the
same activities as the unmodified peptidyl chloromethane as
might be expected, but in each case the modified inhibitor was
less effective than Tyr-Gly-Arg-CH2Cl itself (Table II). Also,
with the radiolabeled forms of the inhibitor, the inactivation of
chymotrypsin-like activity was slightly greater than that of the
trypsin-like activity (Table II). Z-Phe-Gly-Tyr-CHN2, unlike
the peptidyl chloromethane reagents used, inhibited Ala-Ala-
Phe-AMC hydrolysis as well as affected other activities to a
lesser extent (Table II).
Labeling of Proteasomes and Protection by Known Active
Site-directed Inhibitors—The stoichiometry of labeling was de-
termined with the [3H]acetylated inhibitors. With [3H]acetyl-
Tyr-Gly-Arg-CH2Cl, up to 2.5 mol of label were incorporated
per mole of enzyme, whereas for [3H]acetyl-Ala-Ala-Phe-
CH2Cl, where only partial inhibition was achieved, 1.6 mol/mol
were incorporated (Table III). The site-specific nature of the
modifications were investigated by determining rates of inac-
tivation by inhibitors in the presence of substrates and by meas-
uring incorporation of label following pretreatment of protea-
somes with inhibitors known to react at active sites (8, 20, 25).
For all of the radiolabeled inhibitors studied, the incorpora-
tion of radiolabel paralleled the loss of peptidase activity. Also,
incorporation of radiolabel into proteasomes with any of the
labeled inhibitors used was effectively blocked by prior treat-
ment with an active site-directed inhibitor, calpain inhibitor 1,
or 3,4-dichloroisocoumarin. The data obtained with [3H]acetyl-
Ala-Ala-Phe-CH2Cl are shown in Table III. The labeling with
iodinated and acetylated forms of Tyr-Gly-Arg-CH2Cl was also
reduced following pretreatment of proteasomes with 3,4-di-
chloroisocoumarin (see separation of radiolabeled subunits be-
low). Moreover, the rate of inactivation by Tyr-Gly-Arg-CH2Cl
was decreased in the presence of the synthetic peptide sub-
strate Boc-Leu-Ser-Thr-Arg-AMC (data not shown). These re-
sults suggest that although the inhibitors react slowly and
complete inhibition cannot easily be achieved, they do bind at
substrate/inhibitor binding sites and are not reacting nonspe-
cifically under the conditions used for the labeling experiments.
Identification of Labeled Subunits—The radiolabeled inhib-
itors were used to determine the subunits that are involved in
chymotrypsin-like and trypsin-like activities. Following labeling
with 125I-Tyr-Gly-Arg-CH2Cl (Fig. 4, A and B) or [
3H]acetyl-
Tyr-Gly-Arg-CH2Cl, separation of proteasome subunits by re-
verse phase-HPLC showed one major peak of radioactivity and
two minor ones (Fig. 4B). Pretreatment of proteasomes with
3,4-dichloroisocoumarin decreased the incorporation of label
into each of the three peaks (Fig. 4B) as did pretreatment with
Pefabloc, (4-(2-aminoethyl)-benzenesulfonylfluoride) for selec-
tive inhibition of trypsin-like activity (28) (data not shown).
The fractions from the HPLC run of the labeled proteasomes
(Fig. 4A) were analyzed by SDS-PAGE, autoradiography, and
immunoblot analysis. The major peak contained three protein
bands (Fig. 4C). The lower molecular mass subunit (23 kDa)
was shown by autoradiography to be the labeled one, and this
TABLE II
Effect of unlabeled and radiolabeled forms of peptidyl chloromethane
inhibitors on peptidase activities of rat liver proteasomes
Proteasomes were dialyzed against 50 mM Hepes/KOH, pH 7.5, at
4 °C prior to the experiments. Preincubations with unlabeled, radioio-
dinated or [3H]acetylated forms of Tyr-Gly-Arg-CH2Cl were carried out
for 1 h at 20 °C, using 0.1 mg/ml proteasomes with 0.1 mM inhibitor.
Preincubations with the Ala-Ala-Phe-chloromethane inhibitors was
carried out for 1 h at 25 °C with 10 mM inhibitor. At the end of the
preincubations, enzyme samples were diluted into substrate solutions
and assays were carried out as described under “Experimental Proce-
dures.” Abbreviations for substrates are the same as in Table I. Control
incubations were carried out in the absence of affinity label. All data are
the average of results from at least two separate experiments each
carried out in duplicate.
Inhibitor
Activity (% of control) with
substrate
LLVY AAF LSTR LLE
Tyr-Gly-Arg-CH2Cl 26 S 43 73 36 84
20 S 35 80 10 100
[3H]acetyl-Tyr-Gly-Arg-CH2Cl 20 S 45 95 75 105
125I-Tyr-Gly-Arg-CH2Cl 20 S 34 97 55 125
Ala-Ala-Phe-CH2Cl 26 S 49 94 103 98
20 S 51 97 96 92
[3H]acetyl-Ala-Ala-Phe-CH2Cl 20 S 47 93 83 95
Z-Phe-Gly-Tyr-CHN2 26 S 28 58 86 103
20 S 47 64 102 102
FIG. 3. Inhibition of proteasomes by Ala-Ala-Phe-CH2Cl. 20 S
proteasomes (0.5 mg/ml (round symbols)) and 26 S proteasomes (0.2
mg/ml (square symbols)) were incubated with 10 mM Ala-Ala-Phe-CH2Cl
(open symbols) or [3H]acetyl-Ala-Ala-Phe-CH2Cl (solid symbols) in 50
mM Hepes/KOH, pH 7.5, at 25 °C. Samples were removed at given
intervals and assayed using 50 mM Suc-Leu-Leu-Val-Tyr-AMC, incu-
bated for 15 min at 37 °C. Values are expressed as percent of control
activity in samples containing no inhibitor.
TABLE III
Effect of active site-directed inhibitors on the incorporation of label
after treatment with [3H]acetyl-Ala-Ala-Phe-CH2Cl
20 S proteasomes (0.1 mg/ml) were incubated either with 20 mM
3,4-dichloroisocoumarin in 50 mM Hepes/KOH, pH 7.5, at 25 °C for 1 h
or with 100 mM calpain inhibitor 1 in 50 mM Hepes/KOH, pH 7.5, at
37 °C for 30 min. Excess 3,4-dichloroisocoumarin was removed by over-
night dialysis against 50 mM Hepes, pH 7.5. Control samples were
incubated in the absence of inhibitor. [3H]Acetyl-Ala-Ala-Phe-CH2Cl
(10 mM) was added, and the reaction mixture was incubated at 25 °C for
1 h. Proteasomes were removed immediately before and after the incu-
bations and assayed with Suc-LLVY-AMC, incubating for 10 min at
37 °C. The labeled enzyme was applied to a PD10 column (Sephadex
G-25M, 5 cm) equilibrated with 50 mM Hepes/KOH, pH 7.5, in order to
remove excess labeled inhibitor. The protein concentration and radio-
activity was measured in the eluent to determine the stoichiometry of
labeling. Results are the mean of three separate experiments.
Pretreatment with active
site in directed inhibitor
Activity of
proteasomes
(% control)
Stoichiometry of
labeling by
[3H]acetylAAFCK
% Labeling blocked
by pretreatment
with active site-
directed inhibitor
mol/mol
None 100 1.6 0
3,4-Dichloroisocoumarin 8 0.1 93
Calpain inhibitor 1 9 0.3 81
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subunit was identified as RC7 by Western blot analysis using
polyclonal antibodies specific for this subunit (Fig. 4C). The
specificity of the antibodies had been checked against purified
proteasome subunits separated on two-dimensional-PAGE
gels. The two other labeled components were identified as MB1
and LMP7 by immunoblot analysis using appropriate subunit-
specific antibodies (Fig. 4C). Labeling with [3H]acetyl-Ala-Ala-
Phe-CH2Cl gave the same three labeled peaks, but in this case
C7 was a minor labeled peak (data not shown, but see below).
Many attempts were made to purify labeled tryptic peptides
from proteasome preparations labeled with [3H]-acetylated in-
hibitors for sequence analysis by Edman degradation to try to
determine the modified residues. However, because of the com-
plexity of the mixture of peptides generated either from whole
proteasomes or because of the poor recoveries of isolated sub-
units, it proved very difficult to isolate pure peptide and to
obtain sufficient material to provide reliable amino acid se-
quence data. However, in each case when a tryptic digest of the
major radiolabeled subunit of proteasomes labeled with
[3H]acetyl-Tyr-Gly-Arg-CH2Cl (C7) was run on a C18 reverse
phase column, one labeled peak was obtained consistent with
the idea that a single site of the subunit was modified.
All of the results obtained by HPLC analysis were confirmed
by two-dimensional-PAGE (Fig. 5) so that the relative labeling
could be assessed. Identification of the position of proteasome
subunits on two-dimensional-PAGE gels was achieved by N-
terminal sequence analysis and by immunoblotting. With
[3H]acetyl-Ala-Ala-Phe-CH2Cl and
125I-Tyr-Gly-Arg-CH2Cl,
the major spots were MB1, LMP7, and C7, whereas with Z-
Phe-Gly-Tyr-(125I-CHN2), which also inhibited activity meas-
ured with Ala-Ala-Phe-AMC, these subunits were labeled in
addition to one other subunit (Fig. 5D). From its position on
two-dimensional-PAGE gels, this subunit could possibly be
MECL1, but we were unable to identify it directly by immuno-
blot analysis because of the lack of cross-reactivity with the
antibodies to human MECL1.
DISCUSSION
The purification procedure developed for the 26 S protea-
some resulted in higher yields than reported previously (33). 26
S proteasome preparations were found to have greater activity
with synthetic peptide substrates than did the 20 S protea-
somes as found by others (15,16). However, unlike 20 S protea-
somes, they did not show the activation and sigmoidal sub-
strate concentration dependence at high concentrations of the
Z-Leu-Leu-Glu-nap substrate, and they lacked the LLE2 3,4-
dichloroisocoumarin-inhibited peptidylglutamyl peptide hydro-
lase activity of the 20 S complex (46). This may be explained by
the inability of 26 S complexes to undergo the large conforma-
tional changes of the 20 S proteasome that are associated with
FIG. 4. HPLC analysis of radiolabeled proteasome subunits
and the effect of active site-directed inhibitors on labeling of
proteasomes. A, proteasomes were treated with 125I-Tyr-Gly-Arg-
CH2Cl, and subunits were separated by reverse phase-HPLC using a
Vydac C4 column as described under “Experimental Procedures.” Ar-
rows indicate the elution positions of labeled polypeptides (see panel B),
which were identified as LMP7, MB1, and C7 (see panel C). The same
protein elution profile was obtained for proteasomes labeled with
[3H]acetyl-Ala-Ala-Phe-CH2Cl. B, radioactivity determined by counting
4-min fractions (dark bars) from the HPLC separation of subunits
shown in panel A. Shaded bars indicate radioactivity in fractions
obtained from samples of proteasomes that were pretreated with
3,4-dichloroisocoumarin to inhibit chymotrypsin-like and trypsin-like
activity prior to modification with 125I-Tyr-Gly-Arg-CH2Cl. C, identi-
fication of the major radiolabeled subunits from proteasomes labeled
with 125I-Tyr-Gly-Arg-CH2Cl and [
3H]acetyl-Ala-Ala-Phe-CH2Cl.
Samples from radiolabeled subunit peaks identified by HPLC analysis
were run on SDS-PAGE gels and blotted on to nitrocellulose. Left panel,
lane 1, molecular mass standards stained with Ponceau S; lane 2,
fraction 31 (see panel B) of 125I-Tyr-Gly-Arg-CH2Cl treated proteasomes
stained with Ponceau S; lane 3, autoradiograph of lane 2; lane 4,
Western blot with anti-C7 antibodies. Middle and right panels, frac-
tions from peaks obtained after labeling with [3H]acetyl-Ala-Ala-Phe-
CH2Cl where C7 was only a minor labeled component. Middle panel,
lane 1, fraction 25 stained with Ponceau S; lane 2, autoradiograph of
lane 1; lane 3, Western blot with anti-MB1 antibodies. Right panel, lane
1, fraction 21, stained with Ponceau S; lane 2, autoradiograph of lane 1;
lane 3, Western blot with anti-LMP7 antibodies.
FIG. 5. Two-dimensional PAGE analysis of radiolabeled sub-
units. Proteasome subunits were separated by two-dimensional PAGE.
A, proteasomes blotted onto nitrocellulose and stained with Ponceau S.
Arrows indicate the position of labeled subunits shown in the lower
panels. The lower molecular weight subunits were identified as, from
left to right, C7 (2 spots), LMP7, and MB1. B, autoradiogram of protea-
somes treated with 125I-Tyr-Gly-Arg-CH2Cl. C, proteasomes treated
with [3H]acetyl-Ala-Ala-Phe-CH2Cl. D, proteasomes treated with
Phe-Gly-Tyr(125I-CH2Cl).
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the LLE2 activity (47). The other difference found in the cata-
lytic properties of the two types of proteasomes was in the effect
of protein substrates on peptidase activities. The greater effects
of casein on peptidase activities of 20 S rather than 26 S
proteasomes was surprising and not easily explained since
casein is a substrate for both forms of the proteinase. Despite
these differences in catalytic properties of 20 and 26 S protea-
somes, their reactivity with 3,4-dichloroisocoumarin and vari-
ous peptide aldehyde, peptidyl chloromethane, and peptidyl
diazomethane inhibitors was found to be very similar.
The observed decrease in the rate of reaction with peptidyl
chloromethane and diazomethane inhibitors in the presence of
a substrate as well as blocking of incorporation of radiolabel by
prior treatment of proteasomes with known active site-directed
inhibitors, 3,4-dichloroisocoumarin, or calpain inhibitor I sup-
port the view that these reagents react at active/substrate-
binding sites and are therefore suitable for identification of
subunits associated with measured peptidase activities of
proteasomes.
It has recently become clear, following determination of the
three-dimensional structure (8,25) and site-directed mutagen-
esis of the archaebacterial proteasome (20), that the b subunits
play a catalytic role and that the N-terminal threonine residue
is the catalytic nucleophile. However, not all of the eukaryotic
b-type subunits have a putative catalytic threonine residue. In
animal cells, the three g-interferon-inducible subunits (includ-
ing LMP7 and MECL1) as well as the subunits they can replace
(including MB1) all have the N-terminal threonine and are
believed to be catalytic. MB1(X) has previously been identified
as the target for the proteasome inhibitor lactacystin (30).
The results of the labeling studies presented here add to
what is known about catalytic subunits of mammalian protea-
somes. The three chosen inhibitors affected different peptidase
activities and gave rise to distinct labeling patterns of protea-
some subunits separated by HPLC or by two-dimensional-
PAGE. Tyr-Gly-Arg-CH2Cl was the most effective of the pepti-
dyl chloromethane inhibitors tested previously on the trypsin-
like activity of rat liver proteasomes (27). This reagent as well
as the radioiodinated and [3H]acetylated forms were found to
inhibit both trypsin-like activity and chymotrypsin-like activ-
ity assayed with Suc-Leu-Leu-Val-Tyr-AMC. The labeled sub-
units were C7, MB1, and LMP7. [3H]acetyl-Ala-Ala-Phe-
CH2Cl, which inhibited only the activity assayed with Suc-Leu-
Leu-Val-Tyr-AMC, labeled the same three subunits, but
labeling of C7 was only minor. With Z-Phe-Gly-Tyr-(125I-CHN2),
which inhibited the two chymotrypsin-like activities but not
the trypsin-like activity, the major labeled subunit was a dif-
ferent one of higher molecular mass, which was tentatively
identified as MECL1 from its position on two-dimensional-
PAGE gels (44). The labeled subunits are all b-type subunits
that are located in the inner rings of the cylindrical structure.
The labeled subunits identified with the different inhibitors
demonstrate that there is overlapping specificity between the
different peptidase activities of the complex. In particular, the
results presented strongly suggest that there is an interaction
between trypsin-like and chymotrypsin-like activities, and this
view is supported by the very recent structural data for the
yeast proteasome (25).
The predominant labeling of C7 with an affinity label for
trypsin-like and chymotrypsin-like activity is interesting be-
cause this subunit does not possess a putative catalytic N-
terminal threonine residue and is N-terminally blocked (41).
Subunit C10 has previously been implicated in mammalian
proteasome trypsin-like activity from sequence information ob-
tained using an indirect labeling approach with 14C-labeled
N-ethylmaleimide (48). However, it is possible that the labeled
cysteine could affect activity without being part of a catalytic
subunit, and we found no specific labeling of RC10 with our
affinity labels. Interestingly, C7 is the yeast homologue of the
yeast Pre2 subunit, mutants in which affect chymotrypsin-like
activity (22).
Alignment of the different b-type proteasome subunit se-
quences shows that there are only three glycine residues and
two aspartic acid residues that are absolutely conserved (49).
Chloromethane inhibitors usually alkylate histidine residues
in serine proteases, but there is no obviously conserved histi-
dine residue in proteasome subunits. However, other amino
acid residues could be modified by peptidyl chloromethanes,
and the blocking of reactivity of radiolabeled inhibitors by
3,4-dichloroisocoumarin and calpain inhibitor 1 suggests site-
specific modification. An alignment of C7 subunit sequences
with that of PRE1 and the Thermoplasma proteasome b sub-
unit shows that relatively few residues are absolutely con-
served in this group, and of these, Val-20, Lys-41, Gly-141
(Thermoplasma b subunit numbering) are also highly con-
served in related eubacterial sequences (50). The lysine resi-
due, Lys-33 of the mature b subunit is essential for activity in
the Thermoplasma proteasome (20). The equivalent lysine res-
idue in C7 could be modified by a peptidyl chloromethane, but
there are also some fairly well conserved aspartic acid residues
that could react with this type of reagent in a site-specific
manner.
The arrangement of subunits within 20 S proteasomes has
recently been determined both from cross-linking studies of the
mammalian enzyme (14) and from the structure determination
of the yeast proteasome (25). Subunits C7 and MB1 are located
adjacent to each other both within each ring and also across on
the neighboring b ring. It is interesting that these two subunits
are the mammalian homologues of the yeast Pre1 and Pre2
subunits, mutations which were found to affect chymotrypsin-
like activity (21,22). The g-interferon-inducible LMP7 subunit
is believed to replace MB1 (10) and presumably occupies the
same position within the complex. Replacement by and differ-
ences in the levels of the g-interferon-inducible subunits are
known to affect peptidase activities of proteasomes (e.g. Ref.
51). However, because of the close interaction between different
subunits, it is easy to imagine that modification of any subunit
can potentially affect activities at different sites within the
proteasome complex. This underlines the importance of the
direct labeling approach used here to define subunits involved
in catalytic activities that have previously only been well de-
fined by their substrate and their overlapping inhibitor speci-
ficity (26, 27, 52–54).
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